Qiagen (NYSE:QGEN) versus BioLife Solutions (NASDAQ:BLFS) Head-To-Head Survey

BioLife Solutions (NASDAQ:BLFS) and Qiagen (NYSE:QGEN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Earnings and Valuation

This table compares BioLife Solutions and Qiagen”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21 million	18.01	-$4.59 million	$1.16	30.58
Qiagen	$2.09 billion	4.27	$424.88 million	$1.95	22.19

Qiagen has higher revenue and earnings than BioLife Solutions. Qiagen is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for BioLife Solutions and Qiagen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1	8	1	1	2.18
Qiagen	0	9	4	1	2.43

BioLife Solutions currently has a consensus price target of $31.38, suggesting a potential downside of 11.54%. Qiagen has a consensus price target of $43.93, suggesting a potential upside of 1.51%. Given Qiagen’s stronger consensus rating and higher possible upside, analysts plainly believe Qiagen is more favorable than BioLife Solutions.

Risk & Volatility

BioLife Solutions has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.

Insider and Institutional Ownership

93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares BioLife Solutions and Qiagen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	53.29%	2.70%	2.49%
Qiagen	19.49%	14.47%	8.34%

Summary

Qiagen beats BioLife Solutions on 9 of the 14 factors compared between the two stocks.

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.